Perspective Therapeutics
CATX
127 hedge funds and large institutions have $655M invested in Perspective Therapeutics in 2024 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 47 increasing their positions, 23 reducing their positions, and 19 closing their positions.
116% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 19
104% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 23
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
70% more capital invested
Capital invested by funds: $385M → $655M (+$270M)
21% more funds holding
Funds holding: 105 → 127 (+22)
15.5% more ownership
Funds ownership: 57.32% → 72.82% (+16%)
98% less call options, than puts
Call options by funds: $25K | Put options by funds: $1.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$71.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$15.9M |
| 3 |
HBT
Hills Bank & Trust
North Liberty,
Iowa
|
+$13.7M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$8.81M |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$7.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$17.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.49M |
| 3 |
Walleye Capital
New York
|
-$6.58M |
| 4 |
O
OrbiMed
New York
|
-$4.91M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.63M |
CATX Hedge Fund Activity: Q3 2024 in Review
127 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q3 2024, worth a combined $655M — up 70% from $385M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new CATX positions and 19 closed out — a net gain of 22 holders — while 47 added to existing stakes and 23 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $71.4M. The largest seller was Commodore Capital, cutting an estimated $17.4M.
- 127 institutional investors held Perspective Therapeutics (CATX) as of Q3 2024, up from 105 in Q2 2024.
- Funds reported $655M of Perspective Therapeutics stock for Q3 2024, up 70% quarter-over-quarter.
- 41 funds opened new Perspective Therapeutics positions in Q3 2024 and 19 closed out, a net change of +22 holders.
- The largest Perspective Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $71.4M added.
- The largest Perspective Therapeutics seller in Q3 2024 was Commodore Capital, an estimated $17.4M sold.
Based on aggregated 13F filings for Q3 2024.